Product Information

Kit supplied with the following:

• Two (2) vials of 20uL each 1mg/mL BirA biotin-protein ligase (40ug total)
• Two (2) vials of 1.5mL each BiomixA (0.5M bicine buffer solution, pH 8.3)
• Two (2) vials of 1.5mL each BiomixB (100mM ATP, 100mM Mg(OAc)2, 500uM d-biotin)
• Two (2) vials of 1.5mL each additional BIO-200 (500uM d-biotin)

The BirA biotin-protein ligase (EC 6.3.4.15) adds d-biotin covalently to biotin-acceptor peptides/proteins via an ATP intermediate (biotinyl 5"-adenylate) in a highly efficient and targeted manner. The downstream applications of enzymatically biotinylated proteins are varied, important and powerful. The well known biotin-avidin/streptavidin interaction is often exploited for affinity chromatography or protein immobilization on surfaces or substrates. Protein detection via anti-biotin antibodies or avidin/streptavidin-reporter enzyme conjugates (-HRP, -alkaline phosphatase) or fluorescent probes becomes possible. Multimeric forms of biotinylated MHC molecules are popular tools in immunobiology.

When used in combination with our AviTag™ biotin-acceptor peptide amino acid sequence, biotinylation occurs at twice the rate of the natural E. coli BCCP substrate and as much as an order of magnitude or more over other Biotinylation of Peptide sequences. The AviTag™ sequence consequently requires less of the BirA enzyme and shorter incubation times to biotinylate to completion than do other sequences available. If protein instability or protease activities are a concern this may be important to downstream success.

Our BirA enzyme is E. coli wild-type, encoded by the birA gene, and purified to greater than 99% purity by traditional methods. Other names for this enzyme include: biotin ligase; biotin operon repressor protein; birA; biotin holoenzyme synthetase; biotin-[acetyl-CoA carboxylase] synthetase; biotin-[acetyl-CoA-carboxylase] ligase; biotin-[acetyl-CoA carboxylase] synthetase; acetyl CoA holocarboxylase synthetase; acetyl CoA holocarboxylase synthetase; biotin:apocarboxylase ligase; biotin holoenzyme synthetase; HCS.

提供全套的蛋白、肽生物素化的产品，其主要产品包括：生物素蛋白连接酶（BirA）；生物素化菌株；AviTag 载体；生物素化重组蛋白.

Avidity, LLC was founded in 1996 by Millard Cull, Larry Lansing, Dr. Ron Gill, and Dr. Mark Seville to develop peptide tags and molecular biology products based upon the extraordinary affinity of biotin for avidin or streptavidin. While working at Affymax as a researcher, Millard was involved in the discovery of the AviTag technology, saw its commercial potential, and obtained the exclusive rights from Affymax. He started Avidity as a reagent company that sublicenses the right to use the AviTag technology to other companies and sells products for use with the technology.